CAJ | 학술논문

胆道肿瘤（BTC）侵袭性强，早期诊断率仅为10％。研究显示，吉西他滨联合顺铂方案现已成为晚期 BTC 的标准一线化疗方案，但疗效仍不满意。免疫细胞的浸润以及免疫相关的微环境可以抑制多种不同类型的肿瘤。研究发现，肿瘤浸润性 CD8＋细胞毒 T 细胞和 CD4＋T 细胞数量与 BTC 的预后密切相关，提示 BTC 的免疫治疗可能是一种新的手段。
담도종류（BTC）침습성강，조기진단솔부위10％。연구현시，길서타빈연합순박방안현이성위만기 BTC 적표준일선화료방안，단료효잉불만의。면역세포적침윤이급면역상관적미배경가이억제다충불동류형적종류。연구발현，종류침윤성 CD8＋세포독 T 세포화 CD4＋T 세포수량여 BTC 적예후밀절상관，제시 BTC 적면역치료가능시일충신적수단。
Biliary tract cancer (BTC)is one of the most aggressive malignancies with only 1 0% early-stage diagnosis rate.For advanced BTC,regimen of gemcitabine and cisplatin has been regarded as the first line standard combination,but the curative effect is still unsatisfied.Infiltration of immune cells and immune-related microenvironment can inhibit various types of cancers.In BTC,higher frequencies of tumor-infiltrating CD8 + cytotoxic T cells and CD4 + T cells are closely associated with favorable prognosis.These findings have provided the rationale for further development of immunotherapies as a novel treatment modality against BTC.